Figure 2

Population percentage and crude numbers exposed to each luteal support regimen and baseline demographic characteristics. Percentage and number of participants exposed to each luteal support protocol (A), Comparison of median participant age [95% CrI] (B) and median BMI [95% CrI] (C) per luteal support intervention. Reference group was considered to be VP. One way ANOVA analysis was employed as data values abided by gaussian distribution. Two decimal p values and asterisk annotation of significance where p-value < 0.05, it is flagged with one star (*), p-value < 0.01, 2 stars (**), p-value < 0.001, three stars (***). placebo (no exposure), SCP (Subcutaneous progesterone), VP (vaginal progesterone), IMP + VP (intramuscular progesterone and vaginal progesterone), VP + OE (vaginal progesterone and oral estradiol), IMP (intramuscular progesterone), VP + PatchE (vaginal progesterone and patch oestrogen), IMP + OE (intramuscular progesterone and oral estradiol), IMHCG (intramuscular hCG), SCP + VP, Intranasal GnRH-a, OP (oral progesterone), IMP + IME (intramuscular progesterone and intramuscular estradiol), IMP + VP + OE (Intramuscular progesterone, vaginal progesterone and oral estradiol), IMP + VE (Intramuscular progesterone and vaginal estradiol), VP + SCGNRH-a [(Vaginal progesterone and subcutaneous GNRH agonist (GNRH-a)], VP + OE + SCGNRH-a (Vaginal progesterone, oral estradiol and subcutaneous GNRH-a), RP (Rectal progesterone), SCHCG (subcutaneous HCG), VP + DHEA (vaginal progesterone and oral DHEA), IMP + VP + SCGNRH-a (Intramuscular progesterone, vaginal progesterone and subcutaneous GNRH-a), OP + VP (oral progesterone and vaginal progesterone).